Zentiva k.s

Company snapshot

Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe and beyond. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents, bonded t

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zentiva k.s. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Zentiva k.s.

1. Jun 8, 2026 Clinical update

   PERLA — Phase 2

View all clinical trial activity →

• What is Zentiva k.s?

  Zentiva is a pharma organization headquartered in Praha 10, CZ. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• Is Zentiva k.s publicly traded?

  Zentiva k.s appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Zentiva k.s develop or market?

  We link 3 drug profile(s) where Zentiva k.s is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zentiva-k-s#company-drugs.

• What are the latest developments for Zentiva k.s?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zentiva k.s focus on?

  No specific therapeutic focus areas are currently identified for Zentiva k.s in our database.